Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18208222 | 0.99 | SMPD3 (0.52) | SMPD3NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL25339924 | 0.96 | SMPD3 (0.49) | SMPD3NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL18209008 | 0.90 | IRAK4 (0.52) | KMT2AKDM4EIRAK4TGFBR1MEN1 | |
| SCHEMBL21997126 | 0.89 | SMPD3 (0.51) | SMPD3KDM4EIRAK4TGFBR1ADORA3 | |
| SCHEMBL25968681 | 0.89 | L3MBTL1 (0.45) | SMPD3NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL18208233 | 0.89 | SMPD3 (0.55) | SMPD3KMT2AKDM4EIRAK4TGFBR1 | |
| SCHEMBL21997698 | 0.88 | SMPD3 (0.58) | SMPD3KDM4EIRAK4TGFBR1 | |
| SCHEMBL25337175 | 0.88 | TGFBR1 (0.44) | SMPD3NPC1RAB9AKDM4EIRAK4 | |
| SCHEMBL21998169 | 0.87 | TGFBR1 (0.45) | SMPD3NPC1RAB9AKDM4EIRAK4 | |
| SCHEMBL30267170 | 0.86 | SMPD3 (0.61) | SMPD3IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4472967-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12091411-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20200385386-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF | ANGEX PHARMACEUTICAL, INC. | 2020-12-10 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385386-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF | MAP3K20, PNCK, CDC42BPG | SMPD3 2539/4885NPC1 1267/4885RAB9A 1536/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-12091411-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885NPC1 3159/4885RAB9A 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.